Clinical analysis of glucocorticoid in the treatment of bronchial asthma and its influence on serum markers
10.3760/cma.j.issn.1008-6706.2015.23.040
- VernacularTitle:糖皮质激素治疗支气管哮喘实效性及对血清学指标的影响
- Author:
Yong CHEN
- Publication Type:Journal Article
- Keywords:
Glucocorticoids;
Asthma;
Interleukin;
Nitric oxide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2015;(23):3646-3648
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical effect of glucocorticoid in the treatment of bronchial asthma and its influence on serum markers,to provide a reference for clinical treatment.Methods 40 cases with bronchial asthma were selected,and they were randomly divided into observation group and control group,20 cases in each group.The observation group was given montelukast and budesonide inhalation therapy,the control group received montelukast therapy.The lung function after treatment,serum interleukins,serum nitric oxide,the rate -limiting enzyme targets were compared.Results After treatment,FVC%,FEV1 %,PEF% in the observation group were (83.67 ±5.57)%,(89.92 ±6.37)%,(88.01 ±6.04)% respectively,the improvement was better than the control group,the difference was statistically significant(comparison after treatment between the two groups tFVC =3.537;tFEV1 =3.119;tPEF =3.354,all P <0.05).After treatment,IL -4,IL -13,NO,NOS of the observation group were (4.79 ± 0.89)pg/mL,(26.64 ±3.32)pg/mL,(61.13 ±4.49)μmol/L,(33.34 ±2.81 )U /mL,respectively,the improve-ment was better than the control group,the difference was statistically significant(comparison after treatment between the two groups tIL -4 =3.214;tIL -13 =4.051;tNO =3.815;tNOS =3.904,all P <0.05).Conclusion Montelukast combined with glucocorticoids in the treatment of bronchial asthma has good clinical results,which will help to improve the serum inflammatory markers,it is worthy of clinical application.
